Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, GNT Biotech - LARVOL DELTA

Imofinostat, a histone deacetylase inhibitor, enhances anti-tumoral activity on colorectal cancer with an immune checkpoint inhibitor (AACR 2026) - "Transcriptomic profiling was performed using the NanoString IO360 panel, while immune cell alterations and functional markers were analyzed by flow cytometry and immunohistochemistry (IHC). In the CT26 syngeneic mouse model, the combination of imofinostat with avelumab (anti-PD-L1) induced complete tumor regression in 7 of 8 animals...This combination demonstrated superior efficacy compared to the pan-HDAC inhibitor vorinostat and the class I-selective HDAC inhibitor tucidinostat in parallel CT26 models. In the HT29 CRC model co-engrafted with patient-derived PBMCs, an additive anti-tumor effect was observed with the combination of imofinostat and nivolumab (anti-PD-1), which was further enhanced by the addition of aflibercept... Imofinostat synergizes with ICI by targeting mechanisms of immune suppression, including the reduction of M-MDSCs in PBMCs, while concurrently promoting the development of robust cytotoxic and memory T-cell responses. This provides a strong..."

Checkpoint inhibition • Epigenetic controller • IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • CD4 • CD8 • GZMB • IFNG

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database. (PubMed, J Pharm Health Care Sci) - No abstract available

Adverse events • Journal • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Senescent cancer-associated fibroblasts drive early-stage lymph node metastasis in pancreatic cancer through lactate-mediated metabolic-epigenetic rewiring. (PubMed, Cancer Discov) - "We subsequently initiated a clinical trial (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4) in metastatic PDAC patients and reported its preliminary promising results. Collectively, these findings reveal a closed link between cellular senescence and PDAC metastasis, offering the potential senolytic means to improve chemo-immunotherapy efficacy."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • CAFs • CCR4

Selectively eliminating senescent cancer-associated fibroblasts via chidamide and chemo-immunotherapy in metastatic pancreatic cancer: phase 2 clinical trial results (PANDA-1706) (AACR 2026) - P2 | "Here we report the results of the chidamide arm (chidamide and nab-paclitaxel/gemcitabine plus anti-PD-1/CTLA-4). Clinical Trials.gov. identifier: NCT06951997."

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CAFs • CCR4

EARLY ALLOGENEIC TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN HIGH-RISK T-CELL LYMPHOMA: RESULTS OF A PROSPECTIVE PHASE 2 STUDY (EBMT 2026) - P=N/A | "Pts received myeloablative conditioning with BuCy, MeCCNU, and Ara-C or TBI (8 Gy). GVHD prophylaxis consisted of cyclosporine A, MMF, and short-term MTX, plus ATG (10mg/kg) for unrelated or haplo-transplants...The cumulative incidences of acute and chronic GVHD were 45.7% and 62.8%.Off-study pts: Eight of 9(no alloSCT) died of lymphoma, 1 keep CR with chidamide maitaining... Early alloSCT as 1st line consolidation was feasible in two-thirds of pts with low TRM resulting in excellent survival. All but one pts without alloSCT died of lymphoma. Notably, 40% of study pts suffered from HSTCL or MEITL."

Clinical • P2 data • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Immunology • Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

LINEAGE SWITCH FROM B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA TO T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN A PAEDIATRIC PATIENT WITH HOX11 EXPRESSION AFTER 11 YEARS:A CASE REPORT (EBMT 2026) - "Salvage therapies, including the Menin inhibitor Revumenib combined with Venetoclax and Azacitidine, Daratumumab, and the HDAC inhibitor Chidamide, failed to induce remission. This case underscores the aggressive nature of lineage-switched leukaemia.Achieving molecular-level MRD negativity prior to HSCT may reduce relapse risk. Administering palliative targeted agents, particularly menin inhibitors, pre-transplant to achieve molecular remission could potentially be superior to post-transplant palliative therapy."

Case report • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Palliative care • Pediatrics • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Thrombocytopenia • BCL11B • BCL9L • KMT2A • NOTCH1 • NRAS • TLX1 • WT1

A CASE REPORT OF MULTI- DRUG COMBINATION THERAPY FOR RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (EBMT 2026) - "The standard first-line treatment for AITL typically involves the CHOP regimen(cyclophosphamide,doxorubicin, vincristine,and prednisone) or CHOP-like protocols... We conducted a single-case retrospective analysis of a 54-year-old male patient with R/R AITL who had progressed following prior treatment with first-line CHOPE (CHOP plus etoposide) and second-line GDP (gemcitabine, doxorubicin liposome and corticosteroid) regimens. After one cycle of chidamide, mitoxantrone, azacitidine and corticosteroid therapy at our linstitution, the original lesions showed significant shrinkage with partial resolution; however, a new lesion emerged, indicating disease progression...The treatment regimen was subsequently modified to a multi-agent combination: chidamide (20 mg twice weekly), decitabine (10 mg d1-5), mitoxantrone liposome (20 mg d2), bevacizumab (600mg day 1), bortezomib (2mg d1, 4, 8) and dexamethasone (20mg d1-4 ), repeated every 21days... Chidamide, a histone deacetylase..."

Case report • Clinical • Combination therapy • IO biomarker • Bone Marrow Transplantation • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD7

Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL (clinicaltrials.gov) - P1/2 | N=86 | Not yet recruiting | Sponsor: Ruijin Hospital

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Ou Bai, MD/PHD

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD20 • MYC

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Ou Bai, MD/PHD

New P3 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis B • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

A phase II trial of the combination of chidamide and toripalimab in patients with advanced sarcoma (ESMO 2025) - P2 | "The mPFS for well/dedifferentiated liposarcoma patients was significantly prolonged compared to other patients (17.1 months vs. 3.6 months, P <0.001). Conclusions Chidamide with Toripalimab every 21 days was well tolerated and showed promising efficacy in patients with advanced sarcoma, especially for well/dedifferentiated liposarcoma."

Clinical • Metastases • P2 data • Hematological Malignancies • Leiomyosarcoma • Liposarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions. (PubMed, Ann Hematol) - "B-ALL with MEF2D fusions frequently demonstrates multilineage involvement, poor response to conventional chemotherapy, and extramedullary infiltration. Incorporating venetoclax and the histone deacetylase inhibitor chidamide into induction, salvage, or preconditioning regimens may probably improve outcomes for MEF2D-positive patients, though certainly required further clinical validation."

IO biomarker • Journal • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • KRAS • MEF2D • NRAS

CDB0369: Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Ou Bai, MD/PHD | N=20 ➔ 30 | Recruiting ➔ Completed

Enrollment change • Trial completion • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Daihong Liu

New P2 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD22 • CD5 • MYC • TP53

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL (clinicaltrials.gov) - P2 | N=47 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov) - P2 | N=160 | Active, not recruiting | Sponsor: Chinese PLA General Hospital | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2026 ➔ Sep 2025

Enrollment closed • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Chidamide Reprograms the GATA1-HES1 Dysregulation to Restore Megakaryopoiesis in SLE-Associated Immune Thrombocytopenia (EULAR 2026) - No abstract available

Hematological Disorders • Immune Thrombocytopenic Purpura • Inflammatory Arthritis • Thrombocytopenia • Thrombocytopenic Purpura • GATA1 • HES1

Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies. (PubMed, Sci Rep) - No abstract available

Journal • Oncology

VENETOCLAX OR CHIDAMIDE AS POST-TRANSPLANT MAINTENANCE THERAPY IN T-ALL/LBL: REAL-WORLD EVIDENCE OF PROMISING EFFICACY (EBMT 2026) - "In patients with T-ALL/LBL after allo-HSCT, maintenance therapy with chidamide or venetoclax showed a trend toward reduced relapse risk, particularly in the venetoclax group, which achieved a 2-year relapse-free survival rate of 93.33%. However, due to limited sample size, the differences did not reach statistical significance. Larger prospective studies are needed to further validate the efficacy of different maintenance regimens."

Clinical • HEOR • Post-transplantation • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Thrombosis • Transplantation

MYELOABLATIVE CONDITIONING WITH FRACTIONATED BUSULFAN AND CHIDAMIDE IN HIGH-RISK AML/MDS PATIENTS WITH RESIDUAL OR ACTIVE DISEASE PRIOR TO TRANSPLANT (EBMT 2026) - "Fludarabine and cytarabine were given from day -7 to -3, and chidamide (20 mg twice weekly) from day -15 to +2...Acute GVHD prophylaxis consisted of cyclophosphamide (days +3, +4), cyclosporine (from day +5), and mycophenolate mofetil for haploidentical transplants (day +5 to +35)... The combined fractionated busulfan and chidamide regimen is feasible, well-tolerated, and facilitates rapid remission with promising survival in high-risk AML/MDS patients with inadequate pre-transplant disease control, supporting its further evaluation."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Infectious Disease • Myelodysplastic Syndrome • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVE AML (EBMT 2026) - P=N/A | "In this study, we adopted a modified conditioning regimen comprising dual alkylating agents, which was named as MCBC (the combination of melphalan, cladribine, busulfan, and cyclophosphamide)...Rabbit ATG was added in haploid-identical and unrelated-matched donor transplantation. Early initiation of maintenance therapy is recommended if the patient's condition is stable after transplantation, including low-dose azacytidine, venetoclax, FLT3 inhibitors or chidamide... Our study confirms the excellent anti-leukemic capacity and favorable tolerability of MCBC conditioning regimen in patients with R/R or persistent MRD positive AML. Furthermore, the importance of early initiation of maintenance therapy post-transplantation for improving patient survival is underscored."

Clinical • Minimal residual disease • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Transplantation

VENETOCLAX OR CHIDAMIDE AS POST-TRANSPLANT MAINTENANCE THERAPY IN T-ALL/LBL: REAL-WORLD EVIDENCE OF PROMISING EFFICACY (EBMT 2026) - "In patients with T-ALL/LBL after allo-HSCT, maintenance therapy with chidamide or venetoclax showed a trend toward reduced relapse risk, particularly in the venetoclax group, which achieved a 2-year relapse-free survival rate of 93.33%. However, due to limited sample size, the differences did not reach statistical significance. Larger prospective studies are needed to further validate the efficacy of different maintenance regimens."

Clinical • HEOR • Post-transplantation • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Thrombosis • Transplantation

MYELOABLATIVE CONDITIONING WITH FRACTIONATED BUSULFAN AND CHIDAMIDE IN HIGH-RISK AML/MDS PATIENTS WITH RESIDUAL OR ACTIVE DISEASE PRIOR TO TRANSPLANT (EBMT 2026) - "Fludarabine and cytarabine were given from day -7 to -3, and chidamide (20 mg twice weekly) from day -15 to +2...Acute GVHD prophylaxis consisted of cyclophosphamide (days +3, +4), cyclosporine (from day +5), and mycophenolate mofetil for haploidentical transplants (day +5 to +35)... The combined fractionated busulfan and chidamide regimen is feasible, well-tolerated, and facilitates rapid remission with promising survival in high-risk AML/MDS patients with inadequate pre-transplant disease control, supporting its further evaluation."

Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Infectious Disease • Myelodysplastic Syndrome • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation

THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVE AML (EBMT 2026) - P=N/A | "In this study, we adopted a modified conditioning regimen comprising dual alkylating agents, which was named as MCBC (the combination of melphalan, cladribine, busulfan, and cyclophosphamide)...Rabbit ATG was added in haploid-identical and unrelated-matched donor transplantation. Early initiation of maintenance therapy is recommended if the patient's condition is stable after transplantation, including low-dose azacytidine, venetoclax, FLT3 inhibitors or chidamide... Our study confirms the excellent anti-leukemic capacity and favorable tolerability of MCBC conditioning regimen in patients with R/R or persistent MRD positive AML. Furthermore, the importance of early initiation of maintenance therapy post-transplantation for improving patient survival is underscored."

Clinical • Minimal residual disease • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Transplantation

Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series. (PubMed, Front Oncol) - "The regimen shows promise as a potential bridging or debulking strategy, but further research with larger cohorts and longer follow-up is needed to confirm its long-term efficacy. These cases highlight the potential benefits of chemotherapy-free or low-chemotherapy approaches for R/R AML treatment."

Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Gene Therapies • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Transplantation